The lancet oncology

• Latest
• Best
• Search…

• The lancet oncology · Feb 2019

  NHS England statistics and long-term plan.

  no abstract available

  explore more… or not…

• The lancet oncology · Feb 2019

  Editorial

  Big influences on anti-obesity strategies.

  no abstract available

  expand abstract… or just mark as read…

• The lancet oncology · Feb 2019

  Comment Letter

  Limitations of simulation models for cervical cancer screening - Authors' reply.

  no abstract available

  read more… mark as read…

• The lancet oncology · Feb 2019

  Correction to Lancet Oncol 2017; 18: 904-16.

  no abstract available

  expand abstract… mark as read…

• The lancet oncology · Feb 2019

  Randomized Controlled Trial

  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. ⋯ Eli Lilly.

  expand abstract… or not…